Skip to ContentSkip to Navigation
How to find us prof. dr. S. (Steven) de Jong


Dual mTORC1/2 inhibition sensitizes testicular cancer models to cisplatin treatment

Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies

Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in theJAK3gene

MDM2 inhibitors sensitize testicular cancer models to mTORC1/2 inhibitors and cisplatin

Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer F-18-BMS-986192

Targeting metabolism to improve response to immune-checkpoint inhibition in melanoma.

Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities: Determinants of cisplatin sensitivity and novel therapeutic opportunities

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models

Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma

Read more